APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients
Phase of Trial: Phase II
Latest Information Update: 26 Jan 2018
At a glance
- Drugs Gefitinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms APPLE
- 28 Dec 2017 Planned End Date changed from 1 Mar 2027 to 1 Dec 2027.
- 28 Dec 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2022.
- 28 Dec 2017 Status changed from not yet recruiting to recruiting.